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Abstract
Transmissible spongiform encephalopathies, including variant-Creutzfeldt-Jakob disease (vCJD) in humans and bovine
spongiform encephalopathies in cattle, are fatal neurodegenerative disorders characterized by protein misfolding of the
host cellular prion protein (PrP
C) to the infectious scrapie form (PrP
Sc). However, the mechanism that exogenous PrP
Sc
infects cells and where pathologic conversion of PrP
C to the PrP
Sc form occurs remains uncertain. Here we report that similar
to the mechanism of HIV-1 TAT-mediated peptide transduction, processed mature, full length PrP contains a conserved N-
terminal cationic domain that stimulates cellular uptake by lipid raft-dependent, macropinocytosis. Inhibition of
macropinocytosis by three independent means prevented cellular uptake of recombinant PrP; however, it did not affect
recombinant PrP cell surface association. In addition, fusion of the cationic N-terminal PrP domain to a Cre recombinase
reporter protein was sufficient to promote both cellular uptake and escape from the macropinosomes into the cytoplasm.
Inhibition of macropinocytosis was sufficient to prevent conversion of PrP
C to the pathologic PrP
Sc form in N2a cells
exposed to strain RML PrP
Sc infected brain homogenates, suggesting that a critical determinant of PrP
C conversion occurs
following macropinocytotic internalization and not through mere membrane association. Taken together, these
observations provide a cellular mechanism that exogenous pathological PrP
Sc infects cells by lipid raft dependent,
macropinocytosis.
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Introduction
The mammalian prion protein (PrP) is a GPI-anchored cell
surface [1] protein expressed predominantly on neurons, neuro-
endocrine cells and within the lymphoreticular system [2]. PrP is
considered to be the sole causative agent responsible for the
transmission and development of transmissible spongiform en-
cephalopathies such as Creutzfeldt-Jakob disease in humans,
scrapie in sheep and bovine spongiform encephalopathy in cows
[3–8]. Consequently, PrP knock-out mice, that appear phenotyp-
ically normal, remain disease-free and do not produce PrP
Sc
following inoculation with scrapie brain homogenates [9–13]. The
defining step in disease transmission occurs following exposure of
PrP
C to the misfolded, infectious scrapie isoform (PrP
Sc) resulting
in the conformational conversion of wild-type host alpha-helical,
protease sensitive PrP
C form to the beta-sheet, reduced protease
sensitive PrP
Sc conformer [13]. However, the mechanism and
cellular requirements that govern PrP
Sc-mediated conversion of
PrP
C remain unclear.
PrP
C is predominantly found on the cell surface within
detergent-insoluble lipid rafts [14]. Lipid raft microdomains within
the plasma membrane are composed of cholesterol and sphingo-
lipid-rich complexes that associate with GPI-anchored proteins
making them important sites for transmembrane signaling [14–
18]. Prion proteins are continuously recycled between the cell
surface and endosomal compartments, a process that requires
interaction with heparan sulfate molecules and is considered to be
critical to its normal and pathogenic function [19–23]. However,
the mechanism of prion internalization remains controversial and
several different endocytic pathways have been proposed [24–28].
Interestingly, PrP endocytosis does not appear to be a function of
the GPI anchor, but instead is regulated by a phylogenetically
conserved basic amino acid domain (NH2-KKRPKP) located
within the unstructured amino terminus of the mature protein.
Deletion of regions within the N-terminus of PrP
C or point
mutations within the polybasic region have been shown to disrupt
the internalization of prion protein [29–31]. Moreover, fusion of
the NH2-terminal domain to a foreign GPI-anchored protein is
sufficient to induce its endocytosis, suggesting that this property is
intrinsic to this region [22].
Peptide transduction domains (PTDs), also referred to as cell
penetrating peptides (CPPs), are a class of basic peptides that direct
the internalization of fused macromolecules into mammalian cells
[32–34]. The nine amino acid HIV-1 TAT and 86Arg PTDs are
prototypic PTDs that have been used to deliver a wide variety of
cargoes into cells both in vitro and in vivo [32–34]. We previously
determined that the mechanism of cationic PTD-mediated
transduction into cells occurs in three phases: (i) electrostatic
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stimulated uptake by lipid-raft dependent macropinocytosis and
(iii) escape from the endosomal compartment into the cytoplasm
[35,36]. In scanning the signal peptide cleaved PrP
C (residues 23–
231) amino acid sequence, we identified putative transduction
domains in the amino terminus between residues 23–29 and 100–
109. Similar to the TAT PTD, we found that uptake of exogenous
recombinant PrP
C protein in N2a neuroblastoma cells was
sensitive to cholesterol depleting agents and macropinocytosis
inhibitors. We also found that inhibition of macropinocytosis was
sufficient to prevent conversion of PrP
C to PrP
Sc indicating that
pathogenic amplification of PrP
Sc occurs following cellular
internalization by macropinocytosis. Thus, the internalization of
PrP and the TAT PTD appear to share a conserved macro-
pinocytotic mechanism.
Results
To compare the endocytic uptake of exogenous PrP with the
TAT PTD, we co-incubated murine N2a neuroblastoma cells with
fluorescently-labeled recombinant murine PrP (rPrP)-546 (red) and
TAT-Cre recombinase-488 (green) reporter proteins (Figure 1A,
B). Confocal microscopy on live cells showed that both rPrP-546
and TAT-Cre-546 proteins rapidly accumulated within the cell
and co-localized within the same intracellular vesicles (Figure 1B),
suggesting that exogenous rPrP protein and TAT PTD are
internalized within the same intracellular compartments in these
cells. The initial step in TAT PTD transduction requires an ionic
interaction with cell surface glycosaminoglycans (GAGs) that is
thought to be required for stimulation of uptake [32–34]. Likewise,
prion proteins have previously been shown to bind to GAGs,
including chondroitin sulfate, hyaluronic acid and heparin, within
lipid raft microdomains on the plasma membrane [19,20,37] and
deletion of PrP
C residues within the NH2-terminal have been
shown to abrogate these interactions [38]. Similarly, we found that
incubation of N2a cells with anionic heparin prevented membrane
binding and endocytosis of exogenous, fluorescently labeled rPrP
(Figure 1C). Transmission of disease is thought to involve PrP
C
located within lipid rafts since cholesterol depletion at the cell
surface has been reported to attenuate the conversion of PrP
C to
the scrapie form [19,39]. We found that disruption of lipid raft
microdomains by nystatin sequestration of cholesterol both
reduced rPrP membrane binding and blocked internalization,
suggesting that extracellular rPrP was also directed to lipid raft
microdomains and that localization to rafts was required for
uptake of extracellular rPrP (Figure 1C). Remarkably, these
observations paralleled closely the macropinocytotic uptake
mechanism of arginine-rich peptide transduction domains [35,36].
Sequence analysis of the NH2-terminus of PrP revealed the
presence of two putative PTDs with homology to the polybasic
TAT transduction domain (Figure 1A). To ascertain the amino
acid sequence requirements within the amino terminus for PrP
entrance into cells, we generated recombinant fusion proteins with
different PrP domains and Cre DNA recombinase as a reporter for
cellular internalization and endosomal escape (Figure 1A). Previ-
ously we have shown that extracellular recombinant TAT-Cre
fusion protein is rapidly internalized into cells and translocates to
the nucleus where it can excise a transcriptional termination DNA
segment from a loxP-stop-loxP GFP reporter gene to allow GFP
expression [35]. Consistent with TAT-Cre addition, treatment of
reporter cells with rPrP (23–90)-Cre, or the putative N-terminal
PrP transduction domain alone, rPrP (23–29)-Cre, resulted in the
concentration-dependent recombination and expression of GFP
(Figure 2A). Surprisingly given the limited basic composition, rPrP
(23–90)-Cre entered cells at a similar level as the TAT PTD.
However, rPrP (100–110)-Cre fusion showed a significantly
weaker ability to enter cells, achieving a recombination maximum
of only 27% at 2 mM protein (Figure 2A). In contrast, both rPrP
(30–90)-Cre and control Cre protein treatment failed to induce
recombination above background levels (Figure 2A). Co-incuba-
tion of cells with rPrP (23–90)-Cre protein and soluble GAGs
heparin or chondroitin sulfate B, inhibited protein uptake into cells
and subsequent DNA recombination in a dose-dependent manner
(Figure 2B). These observations confirm the presence of a strong
transduction domain at the N-terminus of PrP (residues 23–29)
and a weaker domain between residues 100–110 that are sufficient
for not only endocytic uptake, but also subsequent cytoplasmic
escape of extracellular rPrP. Interestingly, the entire N-terminal
domain of PrP (23–90) was more effective than just the basic PrP
(23–29) domain at inducing recombination, suggesting the
presence of additional elements that may enhance transduction
and/or escape into the cytoplasm.
Endocytic uptake of endogenous PrP
C is controversial and has
previously been reported to occur through either clathrin [24] or
caveolar-dependent forms of endocytosis [20,37]. However,
cellular uptake of the TAT PTD does not occur through either
mechanism [35,40]. To examine the endocytic mechanisms of
extracellular rPrP uptake, we treated N2a cells expressing GFP
tagged caveolin-1-a, a marker of caveolae, with fluorescent rPrP-
546. Parallel to TAT PTD uptake, the vast majority of rPrP-546
(red) containing vesicles did not co-localization with caveolae by
confocal imaging of live cells (Figure 2C). Of the limited number of
co-localized (yellow) vesicles, the majority are not completely
circular (spherical), but partial circles indicating that two
independent vesicles above/below each other are overlapping
and thereby appear to be co-localized. Multiple forms of
endocytosis, including both clathrin and caveolar mediated
endocytosis, require dynamin GTPase activity for vesicle forma-
tion at the cell surface. Expression of a dominant-negative
dynamin-1 (Dyn
K44A) has been used to effectively and selectively
block these endocytic pathways [42]. Consistent with the absence
of Caveolin-1 co-localization, expression of Dyn
K44A in N2a cells
containing a loxP-stop-loxP GFP reporter plasmid, failed to block
cellular uptake of rPrP (23–90)-Cre reporter protein, recombina-
tion and GFP expression (Figure 2D). As a positive control,
Dyn
K44A expression inhibited uptake of a clathrin-mediated
endocytosis marker, fluorescent-labeled transferrin (Figure 2E).
These observations demonstrate that internalization of extracellu-
lar rPrP occurs through a lipid raft-dependent process that is
independent of both caveolar- and clathrin-mediated endocytosis.
Previously we determined that TAT-fusion proteins and
peptides enter cells by lipid raft-dependent macropinocytosis
[35,41], a specialized actin-dependent, fluid phase endocytic
process [41]. To examine the potential involvement of macro-
pinocytosis in rPrP uptake, we treated N2a cells with macro-
pinocytosis inhibitors EIPA, an analogue of amiloride that inhibits
aN a
+/H
+ exchange specific for macropinocytosis [42], or
cytochalasin D, an F-actin elongation inhibitor [43], prior to
incubation with fluorescent-labeled rPrP-546 and measured
internalization using live cell confocal imaging. Treatment of
N2a cells with either macropinocytosis inhibitor prevented the
cellular uptake of rPrP-546, but did not block its cell surface
association (Figure 3A). Cell surface binding of TAT-fusion
proteins has been shown to stimulate macropinocytotic uptake
[35,36,40]. To determine whether extracellular rPrP cell surface
binding can similarly induce macropinocytosis, we co-incubated
N2a cells with a fluorescent marker of fluid phase macropinocy-
tosis, 70-kDa dextran-FITC [44], and increasing concentrations of
Prion Transduction
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significant (p,0.0220.002), concentration-dependent increase in
fluorescent dextran, fluid-phase uptake over steady-state control
levels (Figure 3B). Conversely, both rPrP (residues 30–231) minus
the N-terminal PTD or rPrP (residues 100–231) minus the weak
PTD failed to stimulate macropinocytotic uptake of dextran
(Figure 3C). Taken together, these observations exclude both
clathrin and caveolar endocytosis as the mechanism of exogenous
rPrP uptake, and demonstrate that rPrP can stimulate it’s own
uptake by lipid raft-mediated macropinocytosis.
PrP
C and pathological PrP
Sc have a markedly different COOH-
terminal structural conformation with PrP
Sc having extensive b-
sheet content [3–8]. To determine if pathological PrP
Sc infects
cells by macropinocytosis and if internalization is necessary for
conversion of endogenous PrP
C to the PrP
Sc form, we treated
scrapie susceptible N2aPK1 [12,45] cells with a 10
25 dilution of
strain RML PrP
Sc-infected murine brain homogenates and the
macropinocytosis inhibitor EIPA. Consistent with previous reports
[12,45], treatment of N2aPK1 cells with strain RML PrP
Sc-
infected brain homogenates resulted in conversion of PrP
C into the
proteinase K resistant PrP
Sc form, whereas control non-susceptible
N2aR33 cells were resistant to pathogenic conversion (Figure 4).
Surprisingly, co-incubation of N2aPK1 cells with strain RML
PrP
Sc-infected brain homogenate in the presence of EIPA resulted
in an EIPA concentration-dependent inhibition of PrP
Sc conver-
sion of PrP
C to the pathologic form (Figure 4). Importantly, the
concentrations of EIPA used did not inhibit the cellular density of
N2aPK1 cells (Figure 4B). The requirement of macropinocytosis
Figure 1. Exogenous rPrP is endocytosed into cells and co-localizes with TAT-Cre. (A) Alignment of putative PrP
C transduction domain
with the HIV-1 TAT PTD and schematic of rPrP-Cre recombinase fusion proteins. (B) Co-localization of rPrP (residues 23–231) and TAT-Cre. N2a cells
were treated with rPrP-Alexa546 (red) and TAT-Cre-Alexa488 (green) for 1 hr, then assayed by live cell confocal microscopy. Yellow fluorescence
indicates areas of co-localization. Scale bar=5 mm. (C) N2a cells pre-incubated for 30 min with 50 mg/mL heparin or 5 mM nystatin followed by rPrP-
Alexa546 protein incubation for 2 hr prevented surface binding and internalization, respectively. Scale bar=10 mm.
doi:10.1371/journal.pone.0003314.g001
Prion Transduction
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C suggests that macropinocytotic
uptake of PrP
Sc into cells is a critical step in the propagation of
disease.
Discussion
Fatal transmissible spongiform encephalopathies are fatal
neurodegenerative diseases that occur following host exposure of
PrP
Sc contaminated tissue resulting in conversion of PrP
C form
into the disease causing, partially protease resistant PrP
Sc form [3–
8]. Fundamental mechanistic questions of how exogenous PrP
Sc
protein infects cells, is transported between cells and where
conversion of PrP
C to the pathological PrP
Sc form takes place
remain unclear. However, the observations presented here suggest
that PrP
Sc and the HIV TAT PTD share similar characteristics,
including cell surface association, cellular uptake, intracellular
localization and that these similarities may account for properties
of PrP
Sc during disease propagation. Consistent with cellular
uptake of a short N-terminal leader PrP peptide [46], we found
that mature (processed), full length PrP
C contains a strong N-
terminal transduction domain between residues 23–29 and a much
weaker transduction domain at residues 100–110. Similar to the
TAT PTD, these cationic PrP domains are sufficient to direct the
uptake, internalization and cytoplasmic release of a PrP-CRE
recombinase fusion protein, providing a molecular basis for PrP
Sc
infection.
The endocytic pathway involved in PrP
Sc uptake is unclear. The
observations presented here using dominant-negative dynamin
K44A and inhibitors of macropinocytosis indicate that, similar to
the TAT protein transduction domain, endocytic uptake of PrP
occurred by lipid-raft dependent macropinocytosis, and not
caveloin or clathrin mediated endocytosis. Consistent with PTD
Figure 2. Cellular uptake of rPrP occurs by endocytosis. (A) Reporter cells containing loxP-STOP-loxP GFP reporter gene were treated with
indicated proteins for 1 hr, incubated overnight, then assayed for GFP expression by flow cytometry (6SD). (B) Reporter cells were treated with rPrP
(23–90)-Cre in the presence of heparin or chondroitin sulfate B, washed, incubated overnight, then assayed for GFP-positive cells by flow cytometry
(6SD). (C) N2a cells were transfected with Cav1a-GFP expression plasmid, followed 48 hr later by treatment with rPrP-546 (red) and live cell confocal
microscopy. Scale bar=5 mm. (D) N2a cells co-transfected with pDyn
K44A-HA dominant-negative and pZ/EG loxP-stop-loxP GFP reporter plasmids
were treated with rPrP (23–90)-Cre protein. Scale bar=25 mm. (E) N2a cells co-transfected with pDyn
K44A-HA and pEGFP (constitutive GFP expression)
plasmids (10:1) were incubated with fluorescent transferrin-TMR (red) as a positive control for Dyn
K44A activity. Arrows indicate Dyn
K44A/EGFP
transfected cells. Scale bar=20 mm.
doi:10.1371/journal.pone.0003314.g002
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competed with soluble GAGs. Interestingly, interaction of full
length PrP with the cell surface was sufficient to stimulate
macropinocytosis, while deletion of the N-terminal transduction
domain abrogated this effect. Although the GPI anchor within PrP
is a determinant of lipid-raft association, PrP has been shown to
remain raft associated when the GPI anchor was deleted and was
only abolished by deletion of the N-terminal 23–90 amino acids
further supporting the notion that this domain is important in
cellular raft targeting of exogenous PrP [47]. Interestingly, a PrP
variant, PrP27–30, that lacks the N-terminal transduction domain,
but retains the weaker PTD at residues 100–110, retains a low
level ability to cause pathogenic conversion of PrP
C, suggesting
that the second lysine-rich transduction motif may be sufficient in
the absence of the N-terminal domain to direct cellular entry.
Small amounts of cytoplasmic PrP have been reported to cause
Figure 3. Cellular uptake of rPrP occurs by macropinocytosis. (A) N2a cells were pretreated with either 100 mM EIPA or 5 mM cytochalasin D
for 30 min prior the addition of 2.0 mM fluorescently labeled recombinant rPrP-Alexa546. After 2 hr, cells were washed and analyzed by live cell
confocal microscopy. Scale bar=10 mm. (B) N2a cells were treated with 0.5 mg/mL 70 kDa neutral dextran-FITC for 30 min in the presence of
increasing concentrations of rPrP (0, 0.25, 0.5, 1.0 or 2.0 mM). Fluid phase uptake of dextran was measured by flow cytometry (values6SD, Student’s T-
test: **=p,0.02, ***=p,0.002). (C) N2a cells were treated with 0.5 mg/mL 70 kDa neutral dextran-FITC for 30 min in the presence of 1.0 mM TAT-
Cre, rPrP (23–231), rPrP (30–321) or rPrP (100–231). Fluid phase uptake of dextran was measured by flow cytometry.
doi:10.1371/journal.pone.0003314.g003
Prion Transduction
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ments using PrP-Cre reporter fusion proteins as a phenotypic
marker of endosomal escape suggest that, at least, a small
proportion of extracellular PrP that is internalized can escape
from macropinosomes into the cytoplasm.
During the normal course of infection, host PrP
Sc exposure is
thought to occur following oral uptake of contaminated material.
Although PrP
Sc entry into the nervous system and subsequent
neuronal infection and propagation are critical steps in the
pathogenesis of disease, the mechanistic basis remains poorly
understood. Oral administration of a TAT-beta-galactosidase
reporter protein in mice is sufficient for distribution and enzyme
activity within most tissues, including a small amount detected in
the brain [49]. The presence of a functional PTD in prion protein
provides a mechanistic basis underlying infectious PrP
Sc transport
between cells. Indeed, broad based polyanionic compounds, such
as heparin and PEI, have been reported to inhibit PrP
Sc infection
of cells [50–52], potentially by sequestration of the N-terminal
PTD. However, specific inhibitors of macropinocytosis may
potentially function more efficaciously to prevent initial cellular
uptake of PrP
Sc. Interestingly, Lofgren et al [53] found that a PrP
peptide corresponding to the unprocessed N-terminal signal
sequence and transduction domain (residues 1–28) specifically
blocked PrP
Sc-mediated conversion of PrP
C, whereas other PTD
peptides did not block conversion, suggesting a specific down-
stream effect of cellular uptake.
In conclusion, the observations presented here suggest that
prion protein contains transduction motifs similar to those found
within HIV-1 TAT and that these domains provide a molecular
mechanism for pathological PrP
Sc infection of cells by macro-
pinocytosis and subsequent conversion of PrP
C.
Materials and Methods
Recombinant Proteins
rPrP cloned in a pET28 vector (Novagen) was expressed in BL21
pLysS cells (Novagen) after induction with IPTG for 3 hr. Cells
were resuspended in cold buffer W (50 mM Tris pH 8.0, 250 mM
NaCl, 5 mM EDTA, 1 mM PMSF, 10 mg/mL leupeptin, 0.1 mM
aprotinin,10 mg/mL DNase 1, 10 mg/mL lysozyme), sonicated and
inclusion bodies collected by centrifugation at 30,0006g, 20 min
and solubilized in buffer G (6 M GdmCl, 20 mM Tris pH 8.0,
50 mM Na2HPO4, 100 mM NaCl, 10 mM reduced glutathione,
10 mM imidazole). Cleared lysates were incubated overnight at RT
with shaking, purified on Ni-NTA column, washed with a gradient
of buffer G and buffer B (10 mM Tris pH 8.0, 100 mM Na2HPO4,
0.1 mM oxidized glutathione, 10 mM imidazole) at ratios of 6:0,
5:1, 4:2, 3:3, 4:2, 5:1 and 0:6, respectively. rPrP was eluted in
20 mM Tris pH 8.0, 1 M imidazole and an on-column oxidation
was repeated twice. Fractions were buffer exchanged into 50 mM
Hepes pH 7.0, 100 mM NaCl and 5% glycerol and concentrated
byultrafiltration.rPrP(23–90)-Cre,rPrP(30–90)-Cre,rPrP (23–29)-
Cre, rPrP (100–109)-Cre, TAT-Cre, and control Cre were purified
as previously described [35]. rPrP and TAT-Cre proteins were
conjugated with Alexa546 or Alexa488 (Molecular Probes) so that
the degree of labeling was approximately 1.
Recombination Assays
Reporter T cells
10 containing an integrated loxP-STOP-loxP
GFP expression gene were treated with recombinant protein in the
presence/absence of heparin (Sigma) or chondroitin sulfate B
(Sigma) RPMI for 1 hr at 37uC, 5% CO2. Cells were trypsinized,
washed 26 in PBS and replated in RPMI+10% FBS for 18 h
followed by FACS for GFP positive cells. Cell death was measured
by propidium iodide staining, and using flow cytometry forward/
side analysis.
Confocal microscopy
Murine N2a neuroblastoma cells were grown on glass coverslips
and exposed to 2.0 mM rPrP-Alexa546 for 2 hr, washed and live cell
images were acquired at a depth through the middle of the nucleus
using a BioRad MRC1024 confocal microscope. To determine
colocalization with caveolae, N2a cells were transiently transfected
with 0.2 mg caveolin-1a-GFP expression vector using Fugene-6,
washed and incubated with rPrP-Alexa546 for 2 hr. N2a cells were
pretreated with either 50 mg/mL heparin (Sigma), 5 mM nystatin
(Sigma), 100 mM cytochalasin D (Sigma) or 100 mME I P A( S i g m a )
for 30 min, prior to adding 2.0 mM rPrP-Alexa546 for 2 hr. For co-
localization studies, N2a cells were treated with 2.0 mMr P r P -
Alexa546 and 2.0 mM TAT-Cre-Alexa488. After 2 hr, cells were
washed and corresponding fluorescent confocal images for rPrP-
Alexa546 fluorescence (PMT1) and TAT-Cre-Alexa488 fluorescence
(PMT2) were obtained.
Figure 4. Pathological PrP
Sc conversion of PrP
C requires
macropinocytosis. (A) N2aPK1 cells were exposed to 10
25 dilution
of strain RML scrapie PrP
Sc-infected murine brain homogenate and
increasing concentrations of the macropinocytosis inhibitor EIPA (25, 50
and 100 mM) for 48 hr. Infected cells were then grown on cover slips,
blotted, digested with proteinase K (PK) and probed with anti-PrP
antibodies (A) and Ponceau S staining (B).
doi:10.1371/journal.pone.0003314.g004
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N2a cells were transfected at a ratio of 10:1 with Dynamin
K44A-
HA (pDyn
K44A-HA) expression plasmid (S. Schmid, Scripps
Research Institute) and pZ/EG loxP-STOP-loxP GFP expression
vector (A. Nagy, Univ. Toronto). After 24 hr, cells were treated
with 2.0 mM rPrP (23–90)-Cre for 1 h, trypsinized, washed,
replated in DMEM+10% FBS for 18 h and analyzed for GFP by
FACS. Immunohistochemistry using anti-HA antibody (Babco)
followed by anti-mouse TRITC secondary antibody (Jackson
Labs) was used to verify Dyn
K44A expression. Control Dyn
K44A
and pEGFP vector (Stratagene) (10:1) expressing cells were
incubated in serum-free media for 4 hr prior to addition of
25 mg/mL transferrin conjugated tetramethylrhodamine (Molec-
ular Probes) for 15 min.
Quantification of Macropinocytosis
N2a cells were incubated in DMEM+(serum-free DMEM, 0.1%
BSA and 10 mM Hepes pH 7.4) at 4uC for 30 min. To measure
macropinocytosis, 0.5 mg/mL 70 kDa neutral dextran-FITC
(Molecular Probes) was added to cells treated with increasing
concentrations of recombinant rPrP (0, 0.25, 0.5 1.0, or 2.0 mM),
incubated for 30 min and analyzed by FACS. Background dextran
fluorescence uptake was inhibited by incubation at 4uC for
30 min. Fold increase in dextran uptake was calculated after
subtracting background fluorescence from each sample.
Cell-based PrP
Sc infectivity assay
Except were noted, infectivity assay was performed as described
[12,45]. Briefly, 1610
4 susceptible N2aPK1 cells (gift from C.
Weissmann) and resistant N2aR33 cells, maintained in opti-MEM
(Gibco) plus 10% FBS, were exposed to a 10
25 dilution of strain
RML PrP
Sc-infected murine brain homogenates for 48 hr in the
presence or absence of 25, 50, 100 mM EIPA (Sigma). Cells were
grown to confluence, washed and split 1:10. Replating at 1:10 was
repeated twice. After the last passage 5610
4 cells were plated onto
25 mm Thermanox coverslips (Nunc, Fischer Scientific), grown
for 4 days and then blotted onto a nitrocellulose membrane
(Biorad, 0.45 mm pore size) soaked in lysis buffer (1% Triton
6100, 0.5% deoxycholate, 150 mM NaCl, 50 mM Tris-HCl,
pH 8.0) as described [12,46]. The membranes were dried for 1 h
at 37uC, incubated with 0.5 mg/mL PK in lysis buffer for 90 min
at 37uC followed by treatment with 3 M guanidinium thiocyanate,
10 mM Tris-HCl (pH 8.0) for 10 min. After washing, the
membranes were blocked in 5% non-fat dry milk and probed
with 6H4 anti-PrP antibody (1:1000, Prionics, Zurich) followed by
HRP-conjugated anti-mouse IgG1 antibody. PrP
Sc positive
colonies were visualized using Supersignal West Pico ECL reagent
(Pierce Biotechnology).
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